NDC 51144-050

ADCETRIS

Brentuximab Vedotin

ADCETRIS is a Intravenous Injection, Powder, Lyophilized, For Solution in the Human Prescription Drug category. It is labeled and distributed by Seagen Inc.. The primary component is Brentuximab Vedotin.

• Product ID: 51144-050_1f8ca09e-c5d3-422a-87ee-c2c6155e75af
• NDC: 51144-050
• Product Type: Human Prescription Drug
• Proprietary Name: ADCETRIS
• Generic Name: Brentuximab Vedotin
• Dosage Form: Injection, Powder, Lyophilized, For Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2011-08-25
• Marketing Category: BLA / BLA
• Application Number: BLA125388
• Labeler Name: SEAGEN INC.
• Substance Name: BRENTUXIMAB VEDOTIN
• Active Ingredient Strength: 50 mg/10.5mL
• Pharm Classes: CD30-directed Immunoconjugate [EPC],Immunoconjugates [CS],CD30-directed Antibody Interactions [MoA],Microtubule Inhibition [PE]
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 51144-050-01

1 VIAL, SINGLE-DOSE in 1 BOX (51144-050-01) > 10.5 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2011-08-25
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 51144-050-01 [51144005001]

ADCETRIS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION

• Marketing Category: BLA
• Application Number: BLA125388
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: EA
• Marketing Start Date: 2011-08-25

Drug Details

Active Ingredients

Ingredient	Strength
BRENTUXIMAB VEDOTIN	50 mg/10.5mL

OpenFDA Data

• SPL SET ID: 3904f8dd-1aef-3490-e48f-bd55f32ed67f
• Manufacturer:
  • Seattle Genetics, Inc.
• UNII:
  • 7XL5ISS668
• RxNorm Concept Unique ID - RxCUI:
  • 1147323
  • 1147327

Pharmacological Class

• CD30-directed Immunoconjugate [EPC]
• Immunoconjugates [CS]
• CD30-directed Antibody Interactions [MoA]
• Microtubule Inhibition [PE]